10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics, Inc.

Terex Corporation (($TEX)) has held its Q2 earnings call. Read on for the main highlights of the call. Terex Corporation’s latest earnings call str...

Terex Corporation Lifts Outlook After Strong Earnings Call

Torex Gold (($TSE:TXG)) has held its Q2 earnings call. Read on for the main highlights of the call. Torex Gold’s latest earnings call painted a bro...

Torex Gold Earnings Call Balances Growth and Costs

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on 10x Genomics today and set a price target of $50.00. Arias covers the Healthcare se...

Stifel Nicolaus Sticks to Its Buy Rating for 10x Genomics (TXG)

Torex Gold Resources ( ($TSE:TXG) ) has provided an announcement. Torex Gold reported Q2 2026 production of 96,297 gold equivalent ounces, in line ...

Torex Gold Delivers Strong Q2 Cash Flow and Raises Cost Guidance as Grades Set to Improve

Barclays analyst Adam Seiden maintained a Buy rating on Terex today and set a price target of $70.00. Seiden covers the Industrials sector, focusin...

Barclays Sticks to Their Buy Rating for Terex (TEX)

Terex ( ($TEX) ) has provided an update. On February 2, 2026, Terex Corporation completed its previously announced acquisition of REV Group, Inc. a...

Terex Completes REV Group Acquisition, Enhancing Vehicle Portfolio

Addentax Group ( ($ATXG) ) just unveiled an announcement. On July 27, 2026, Addentax Group Corp. entered into a Loan Conversion Agreement with lend...

Addentax Group Converts Debt to Equity via Shares

The latest announcement is out from Terex ( ($TEX) ). On July 20, 2026, Terex Corporation announced plans to host a conference call to review its s...

Terex to Review Q2 2026 Results via Webcast

In a report released today, Adam Seiden from Barclays maintained a Buy rating on Terex, with a price target of $70.00. Seiden covers the Industrial...

Barclays Remains a Buy on Terex (TEX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 10x Genomics (TXG), Elevance Health (ELV) and John...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TXG	$56.09	0.00%	2.87M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TXG	$56.09	0%	2.87M
3
4
5
6

TXG

Get 10x Genomics, Inc. Data in Excel

Get 10x Genomics, Inc. Data in Excel